BioVaxys Technology Corp. Announces Significant Debenture Transition

Author: Logan Wright Updated: 10-22-2025 03:55 AM

BioVaxys Technology Corp. Announces Conversion of Debentures

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) has recently revealed a significant financial update regarding the conversion of outstanding unsecured convertible debentures held by certain investors.

Details of the Debenture Conversion

In recent communications, the Company announced that outstanding debentures, totaling $335,670, are now convertible into common shares. This conversion offers holders flexibility, allowing them to opt for shares at the prevailing market price on the Canadian Securities Exchange (CSE) at the time of conversion notice.

The conversion constitutes a total principal amount of $160,670, accompanied by accrued interest, bringing the total to $162,210.67 payable in shares. In receipt of this announcement, the Company plans to issue 954,179 common shares at a conversion price of $0.17 each, emphasizing transparency and compliance in entry with regulatory approvals from the CSE.

Impact on Shareholders and Future Projections

This proactive step reflects BioVaxys's commitment to enhancing shareholder value. By unlocking the potential of these debentures, the Company takes meaningful steps toward broadening its financial resources, encouraging further investment in ongoing and future projects.

Each issued share correlates with an effort to fuel further developments within its clinical-stage biopharmaceutical pipeline, notably focusing on innovative immunotherapy solutions. By capitalizing on this conversion process, BioVaxys strengthens its strategic positioning to tackle critical challenges in the biopharmaceutical sector.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. is dedicated to pioneering the biopharmaceutical landscape with its innovative DPX™ immune-educating technology platform. This platform focuses on enhancing treatments for issues such as cancer, infections, and food allergies. Their unique approach is designed to activate specific immune responses aimed at delivering lasting benefits to patients.

The clinical pipeline showcases exciting developments including maveropepimut-S (MVP-S), which is currently in Phase IIB clinical trials targeting severe forms of Diffuse Large B Cell Lymphoma (DLBCL) and others. This product utilizes specialized cancer antigens to trigger robust immune reactions against tumors, thereby optimizing therapeutic outcomes.

Connecting with BioVaxys

For ongoing updates, interested parties can seek information about BioVaxys Technology Corp. through their official channels, keeping informed on their advancements is crucial. As they navigate through the intricacies of clinical development, partnerships in emerging biotech markets will be essential for future success.

Frequently Asked Questions

What are the recent announcements from BioVaxys Technology Corp.?

The Company announced the conversion of outstanding unsecured convertible debentures, enhancing its financial flexibility and shareholder value.

What is the conversion price of the shares being issued?

The shares will be issued at a conversion price of $0.17 each.

How many shares will be issued in relation to the debentures?

A total of 954,179 common shares will be issued to satisfy the conversion of the debentures.

What technology does BioVaxys focus on developing?

BioVaxys specializes in developing novel immunotherapy solutions using the DPX™ technology platform for various diseases, including cancers and infections.

How can investors stay updated on BioVaxys activities?

Investors can follow BioVaxys through their official website and social media channels for the latest updates and developments.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.